Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tradr 2X Short TSLA Daily ETF
TSLQ
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
IMNN Imunon
- 0.8815
- +0.0215+2.50%
Close Apr 29 16:00 ET
12.89MMarket Cap-0.54P/E (TTM)
0.8996High0.8316Low48.78KVolume0.8600Open0.8600Pre Close41.70KTurnover0.39%Turnover RatioLossP/E (Static)14.62MShares3.650052wk High3.04P/B10.92MFloat Cap0.640052wk Low--Dividend TTM12.39MShs Float145293.7500Historical High--Div YieldTTM7.91%Amplitude0.4800Historical Low0.8540Avg Price1Lot Size
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Imunon Stock Forum
First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian Cancer - ASCO 2025 Preview
Can IMUNON's Immunotherapy Transform Ovarian Cancer Treatment? Phase 3 Trial Coming After 13-Month Survival Advantage
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
Positive
First immunotherapy showing clinical benefits in ovarian cancer survival
13-month overall survival benefit in Phase 2 trial
Improved hazard ratio from 0.74 to 0.69
62% of long-term survivors from IMNN-001 treatment arm
Positive FDA feedback for Phase 3 trial advancement
9% decrease in operating expenses
Negative
Net...
Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.62) per share which beat the analyst consensus estimate of $(1.69) by 4.14 percent. This is a 25 percent increase over losses of $(2.16) per share from the same period last year.
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages
Imunon Announces New Immunogenicity Data From Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of Covid-19
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Wednesday, 26th February at 8:05 am
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology
IMNN-101 induced 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4
IMNN-101 continues to show an acceptable safety profile
LAWRENCEVILLE, N.J...
The translational data from IMUNON's OVATION 2 Study reveals several critical insights into IMNN-001's mechanism of action and therapeutic potential. The 20% increase in IL-12 levels with the higher dose (100mg/m2) is particularly significant, as IL-12 is a important cytokine that enhances anti-tumor immune responses. The localized effect in the peritoneal cavity, with minimal systemic presence, suggests an optimal therapeutic window that maximizes effi...
Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial
1 MINUTE AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose
Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment
IMNN-001 continues ...
No comment yet